Fremanezumab for the Preventive Treatment of Chronic Migraine-Reference-Cited by-同舟云学术

Fremanezumab for the Preventive Treatment of Chronic Migraine

Published:2017-11-30 Issue:22 Volume:377 Page:2113-2122
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Silberstein Stephen D.,Dodick David W.,Bigal Marcelo E.,Yeung Paul P.,Goadsby Peter J.,Blankenbiller Tricia,Grozinski-Wolff Melissa,Yang Ronghua,Ma Yuju,Aycardi Ernesto

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709038

Cited by 606 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine;Headache: The Journal of Head and Face Pain;2024-09-13

2. Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population;The Journal of Headache and Pain;2024-09-12

3. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study;European Journal of Neurology;2024-09-04

4. Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial;Headache: The Journal of Head and Face Pain;2024-09-02

5. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine;Cephalalgia;2024-09